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RNA silencing technology and methods based thereupon are important in today’s medical 
biotechnology. Small interfering RNA (siRNA) high-throughput screening has a variety of 
possibilities in pharmaceutical development, for instance in finding the site of the effect for a 
certain drug, and confirming its effect and working mechanism. There are various commercial 
products available for the transfection of siRNA molecules into cell lines of interest. Transfection 
of primary and stem cells, on the other hand, has been found difficult and careful optimization of 
the methods and reagents used is always needed.  
The purpose of this thesis was to optimize the conditions of siRNA transfection for two cancer 
stem cell cultures and for three other cancer cell lines that have been found hard-to-transfect. 
Out of eight different commercially available transfection reagents, there were two possible 
candidates for use as common chemical transfection reagents, SiLentFect (Bio-Rad) and 
HiPerFect HTS (Qiagen). For transfection of two cancer stem cell cultures and for one hard-to-
transfect cell line, Nucleofection technology was found an efficient method. 
The commissioner of this thesis, VTT medical biotechnology, Merja Perälä’s research team, has 
been working with high-throughput screening (HTS) and siRNA technology. The optimized 
methods will be used in siRNA-high-throughput screenings at VTT. 
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siRNA TRANSFEKTION OPTIMOINTI 
RINTASYÖPÄ- JA GLIOMASOLUVILJELMILLE 
RNA-hiljentämiseen pohjautuvat menetelmät ovat tärkeitä työkaluja biolääketieteellisessä 
tutkimuksessa. siRNA-tehoseulontateknologialla on monia mahdollisuuksia lääkekehityksessä 
esimerkiksi lääkkeiden vaikutuskohteiden löytämisessä, varmistamisessa ja lääkkeiden 
vaikutusmekanismien tutkimuksessa. SiRNA-molekyylien transfektioon solulinjoihin on 
olemassa monia kaupallisia reagensseja. Etenkin primäärisolujen transfektio on usein kuitenkin 
vaikeaa ja vaatii yksittäisille solutyypeille optimoituja menetelmiä.  
Tämän opinnäytetyön tarkoituksena oli optimoida siRNA-transfektio-olosuhteet kahdelle valitulle 
rinta- ja aivosyöpäprimäärisolulinjalle sekä kolmelle muuten vaikeasti transfektoituvalle 
solulinjalle. Kahdeksasta kaupallisesta transfektioreagenssista kahden, SiLentFect (Bio-Rad) ja 
HiPerFect (Qiagen), todettiin toimivan toivotun mukaisesti ja näitä reagensseja voitaisiin käyttää 
yleisesti transfektioissa. Nukleofektointi todettiin toimivaksi transfektiometodiksi 
primäärisolulinjoille ja vaikeasti transfektoitavalle solulinjalle. Optimoituja menetelmiä on 
tarkoitus hyödyntää VTT:n siRNA-tehoseulontaprojekteissa.  
Opinnäytetyö tehtiin VTT:n Turun yksikössä, lääkekehityksen biotekniikalla, Merja Perälän 
tutkimusryhmässä. 
 
.  
 
 
 
 
ASIASANAT: 
Transfektio, Nukleofektio, RNAi, siRNA, Rintasyöpä, Gliooma, Syöpä Kantasolu, 
Aldehydidehydrogenaasi  
 
 
CONTENT 
LIST OF ABBREVIATIONS 7 
1 AIM OF THE THESIS 6 
2 INTRODUCTION 8 
3 CANCER AND CANCER CELLS 9 
3.1 Cancer Stem Cells (CSC) 10 
3.2 Breast cancer cells 14 
3.3 Glioma cells 14 
4 TRANSFECTION 16 
4.1 Chemical transfection 17 
4.2 Physical transfection 18 
4.3 Nucleofection 19 
5 RNA INTERFERENCE 20 
5.1 RNAi and Cancer 22 
6 MATERIALS AND METHODS 23 
6.1 Stem Cells and Cancer Cell Cultures 23 
6.2 High Throughput (HT) Transfection 24 
6.3 Nucleofection 27 
6.4 Aldefluor® Assay 30 
7 RESULTS 32 
7.1 Chemical Transfection 32 
7.2 Nucleofection 46 
3.1.1 Stem cell markers 12 
4.1.1 Liposomal transfection 17 
4.1.2 Non-liposomal transfection 18 
6.2.1 Transfection Reagents 25 
6.2.2 Transfection protocol 26 
6.2.3 CellTiter-Glo® (CTG) –measurement 27 
6.2.4 Optimization 27 
6.3.1 Optimization – Nucleofection of pmaxGFP® Vector 28 
6.3.2 Cell Viability and Transfection Efficiency 29 
6.3.3 Nucleofection of siRNA 29 
6.4.1 Determination of ALDH activity 30 
6.4.2 Multilabel Reader and Fluorescence Microscope 31 
 
 
7.3 ALDH activity 55 
8 DISCUSSION 59 
LITERATURE AND REFERENCES 62 
APPENDICES 
Appendix 1. Complete Cell Growth Media 
FIGURES 
Figure 1. Mutations and Epigenetic changes in stem and progenitor cells. ................. 11 
Figure 2. Rat neurosphere (p350) (Invitrogen.com) and breast cancer stem cell 
(Celprogen) (p16) cultures. ......................................................................................... 12 
Figure 3.Glioblastoma A172 (p350) and U87 MG (p42) cell cultures. .......................... 15 
Figure 4. Lipofection. .................................................................................................. 18 
Figure 5. RNA interference. ........................................................................................ 21 
Figure 6. MCF-7 transfection results. .......................................................................... 33 
Figure 7. MCF-7 transfection results with HiPerFect and SiLentFect .......................... 34 
Figure 8. BT-474 transfection results. ......................................................................... 35 
Figure 9. BT-474 transfection results with TrueFect .................................................... 36 
Figure 10. Breast epithelial cell transfection results .................................................... 37 
Figure 11. Breast epithelial cell transfection results with SiLentFect and HiPerFect .... 38 
Figure 12. Breast CSC transfection results. ................................................................ 39 
Figure 13. Breast CSC transfection results with SiLentFect ........................................ 40 
Figure 14. U-87 MG transfection results. .................................................................... 41 
Figure 15. U-87 MG transfection results with SiLentFect and X-tremeGENE .............. 42 
Figure 16. A-172 transfection results .......................................................................... 43 
Figure 17. A-172 transfection results with HiPerFect .................................................. 44 
Figure 18. Glioma CSC 1904 transfection results ....................................................... 45 
Figure 19. Optimization of Nucleofection™ Conditions ............................................... 46 
Figure 20. Nucleofection of  CSC 1904 with EN 138 program and Cell Line Kit P3. .... 48 
Figure 21. pmax™GFP nucleofected breast epithelial cells and CSCs. ...................... 49 
Figure 22. Nucleofection of Breast Epithelial cells. ...................................................... 50 
Figure 23. Nucleofection of Breast CSC. .................................................................... 51 
Figure 24. Optimization of Nucleofection™ Conditions ............................................... 53 
Figure 25. Nucleofection of BT-474............................................................................. 54 
Figure 26. Nucleofected BT-474 cells. ........................................................................ 54 
Figure 27. ALDHbr detection of LNCaP and Breast CSC cell cultures. ......................... 56 
Figure 28. ALDEFLUOR® stained LNCaP cells .......................................................... 56 
Figure 29. ALDHbr detection of SK-BR 3 and Breast CSC cell cultures. ...................... 57 
Figure 30 ALDEFLUOR® treated SK-BR 3 cells. ........................................................ 58 
Figure 31. ALDEFLUOR® treated breast CSC cells, .................................................. 58 
Figure 32. ALDEFLUOR® stained SK-BR 3 cells ....................................................... 58 
 
 
TABLES 
Table 1. Commercial transfection reagents tested with six different cell cultures. ....... 25 
Table 2. SiRNA’s used in the transfections ................................................................. 26 
Table 3. MCF-7 transfection results with the highest transfection efficiencies. 
Transfection efficiency is shown relative to negative control (siNEG). ......................... 33 
Table 4. BT-474 transfection results with the highest transfection efficiencies. ........... 35 
Table 5. Breast Epithelial Cell transfection results with the highest transfection 
efficiencies. ................................................................................................................. 38 
Table 6. Breast CSC transfection results with the highest transfection efficiencies. .... 40 
Table 7. U-87 MG transfection results with highest transfection efficiencies. .............. 42 
Table 8. A-172 transfection results with highest transfection efficiencies. ................... 44 
Table 9. CSC 1904 transfection results. ...................................................................... 45 
Table 10. Results of CSC 1904 pmaxGFP™ nucleofection. ....................................... 47 
Table 11. Results of Breast Epithelial cell pmaxGFP™ nucleofection. ........................ 49 
Table 12. Results of Breast CSC pmaxGFP™ nucleofection ...................................... 51 
Table 13. Results of BT-474  pmaxGFP™ nucleofection ............................................ 53 
Table 14. Results of ALDEFLUOR® Assay for Adherent Cells. .................................. 55 
  
  
 
 
LIST OF ABBREVIATIONS 
 
ALDH aldehyde dehydrogenase 
ALDHbr ALDH bright (intracellular marker) 
ATP adenosine triphosphate 
CD44 cell-surface glycoprotein 
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SiRNA short interfering RNA  
+ve positive  
-ve negative  
6 
 
1 AIM OF THE THESIS 
This thesis was conducted in Merja Perälä´s group at the Medical 
Biotechnology department of VTT. I want to thank Merja Perälä for the 
opportunity to conduct my Bachelor’s thesis at VTT, and I am grateful for the 
advice and guidance received from Saija Haapa-Paananen and the other 
members of the team. 
The aim of this thesis was twofold with the main focus on efficient transfection 
of two cancer stem cell cultures and three other cell lines with siRNA. The 
second focus was on detecting the stem cell properties of cultured cancer cells 
by their specific ALDH enzyme activity. Transfection optimization was 
performed in order to validate the efficacy of commercially available transfection 
reagents. It was also possible to discover a competing reagent for the one 
transfection reagent now mainly used at VTT Turku. ALDH enzyme activity was 
tested in order to prove its use as a stem-cell marker and as an identifying 
reagent for cells with stem cell properties. 
Merja Perälä’s group focuses on high-throughput library screenings, mainly 
detecting the influence of drug candidates and the effect of small-molecules on 
breast cancer and prostate cancer cells as well as on glioma cells. In this thesis, 
breast cancer cells and glioma cells were used. 
Today, there are multiple variations of transfection reagents on the market and 
the manufacturers are being pressurized to develop new sets of formulas and 
methods all the time. The high-throughput format is still quite a new area of 
research where transfection reagents and ready-to-use protocols are not always 
available. For this particular reason optimization of a new reagent is always 
needed before the actual research work can begin. Each cell culture and cell 
line has its own characteristics which also determine the requirement for 
optimization since no general transfection protocol can be adopted. 
SiLentFect™ (Bio-Rad, Hercules, CA) is a transfection reagent commonly used 
at VTT Turku at the moment. After the last optimization of transfection reagents, 
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done in 2004 and 2008 at VTT, the supply of commercial reagents has been 
extended and developed frequently so it was found beneficial to test new 
variants of transfection reagents. A Nucleofector™ device was recently 
purchased to VTT Turku to obtain efficient transfection results for primary cell 
and cancer stem cell cultures. A second part of the first aim of this thesis was to 
optimise the electro pulse programs and cell line kits of the Nucleofector™ 
device. The study of cancer stem cells has drawn a lot of interest in the past few 
years. For the identification of stem and stem-like cells there are some 
commercial kits. One of them is the ALDEFLUOR® Assay, in which cells with 
stem cell properties are fluorescently tagged. The second aim of this thesis was 
to test this kit for new cancer stem cell lines with a multilabel reader and to 
visually capture the fluorometric signal. 
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2 INTRODUCTION 
High-throughput screening (HTS) is a set of methods which aims to analyze a 
large number of samples simultaneously. HTS is especially used in drug and 
other compound screenings where thousands of potential molecule candidates 
can be tested without laborious work or unreasonable cost. Large libraries 
containing thousands of different candidates can be screened in a short time. 
HTS is based on automated handling of sample volumes from micro- to 
nanoliters, detecting specific signals and analyzing the data gained. HT screens 
are carried out in the 384-format and even 1536-format, enabling the use of 
lower volumes and screening numerous samples per day. 
At VTT, multiple large scale HTS screening projects for both compound and 
siRNA screens have been carried out. Breast cancer and glioma research is 
one of the main focuses. An example of compound HTS screening 
accomplished at VTT involved systematic examination of the efficacy of 
commercial drug-like molecules against prostate cancer cells (Iljin et al 2009). 
High-throughput microRNA (miRNA) transfection, where 319 pre-miRs were 
transfected, was applied in the study of estrogen receptor signaling in breast 
cancer cell lines (Leivonen et al 2009). HTS screening employed in RNA 
interference (RNAi), where the influence of four specific genes on cell growth 
was studied (Vainio et al 2011), is an example of one of the recent HTS assays 
applied at VTT.  
  
9 
 
3 CANCER AND CANCER CELLS  
Cancer is defined as a disease where abnormal cells divide without control with 
the ability to invade other tissues in the body. To be precise, cancer is a 
heterogeneous set of diseases and different types of cancers are very different. 
Typically the organ or the cell type where cancer originates, names the disease 
(National Cancer Institute).  
Cancer is a malignant tumor. Two types of tumors exist: benign and malignant 
ones. A shared feature is that they are both deformations of tissue, and mainly 
not dependent on the growth factors of the body. They are unintentional and 
detrimental to the host. The division into benign and malignant simplifies the 
understanding of the biology of a cancer (Cooper 2000). Benign tumors are 
local and slow-growing, and usually do not lead to the patient’s death even 
when left untreated. Cancers, malignant tumors, on the other hand are fast 
growing and have the tendency of invasion into other parts of the body by 
metastasis. Cancer cells have lost the cell-to-cell inhibition (Joensuu et al 
2007). A benign tumor is not a cancer where as a malignant one is and if left 
untreated, the latter leads to the death of a patient. 
There are multiple reasons for the tissue deformation and not only one exact 
cause for the development of a tumor. Many research methods are used for 
understanding the development of tissue outgrowth: clinical and epidemiological 
observations, laboratory animal testing, tissue culturing and molecular biological 
methods. With laboratory animals, for example, and by cell culturing, detailed 
information is obtained about the development of a cancer in controlled testing 
conditions. This type of research gives us detailed information about the 
influence of certain external factors on the origin of a cancer. Cell and molecular 
biology based research methods have given for example specific information 
about the genes affecting tumor development and mutations in DNA, which both 
have an important pathological significance for abnormal cell growth and for the 
maturation and progression of a cancer. (Joensuu et al 2007)  
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Carcinogenesis is a two-stage mechanism where a malignant tumor is 
developed. These two processes are called initiation and promotion. Initiation is 
a stage where the DNA undergoes a mutation and this way sensitizes the whole 
cell to be mutated (Joensuu et al 2007). In most cases, genes damaged in the 
initiation stage are so called proto-oncogenes and they are found to play an 
important role in the development of a cancer. The second stage, promotion, is 
the actual phase for the tumor development where the target tissue has been 
shown to overactivate its own cell division. Promotion is a stage of vital damage 
leading from a tumor to a cancer. After the development of carcinogenesis, the 
progression phase finalizes the development of a cancer. In progression, the 
malignant tumor matures and becomes independent of the normal cell growth 
factors, having the tendency to form metastases (Joensuu et al 2007, Visvader 
2011). Cancer is usually diagnosed when reaching this progression phase.  
3.1 Cancer Stem Cells (CSC) 
Normal stem cells are the cells giving rise to all the complex tissues seen in 
adults. They have the ability to undergo self-renewal over and over again and to 
generate mature cells for specific tissues through differentiation (Reya  et al 
2001). The self-renewal is crucial for stem cell function. Normal stem cells have 
a finely planned balance regulation between self-renewal and differentiation. 
Understanding the regulation of normal stem cell self-renewal has also been 
found to be the base for understanding the regulation of cancer cell 
proliferation, since a malignant tumour can be considered a disease of 
unregulated self-renewal (Reya et al 2001).  
The study of cancer stem cells (CSC) got attention when John Dick’s team 
(Bonnet, Dick 1997) provided evidence that the growth and propagation of 
leukaemia were driven by a small population of cancer cells having the ability to 
self-renew unendingly. The cells were designated as cancer stem cells. Since 
this, CSCs have been identified and isolated from tumours initiating in the 
breast, the brain, the prostate, the lung etc. (Charafe-Jauffret et al 2008).  
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The thought of stem cell driven cancer provides a whole new way approach to 
oncogenesis, suggesting new methods can be used for the prevention, 
detection and for the treatment of cancers, especially those with a metastatic 
tendency where no therapeutic treatment exists. 
In most tissues, stem cells are rare, but the hypothesis exists that normal stem 
cells undergo an oncogenic transformation resulting in the origination of a 
cancer (Figure 1). There have also been arguments for a transformation of  the 
so called progenitor cells resulting in cancer (Jordan et al 2006, Visvader 2011). 
Progenitor cells are developmentally advanced yet immature cells; the early 
descendants of stem cells with the ability of differentiation but restricted division 
(Charafe-Jauffret et al 2008; van der Hoogen et al 2010).   
 
Figure 1. Mutations and Epigenetic changes in stem and progenitor cells. 
Normal stem cell are the ones forming differentiated tissues in an adult individual. 
Before forming the differentiated tissues, stem cells go through a progenitor cell stage. 
These stem and progenitor cells are vulnerable to oncogenic hits and mutations, that 
might cause the cells to form a tumour. In here, it is shown a hypothesis of a built-in 
CSC population which can survive general cancer treatments and the disease might 
relapse (Visvader 2011). 
CSCs and normal stem cells  have been shown to share many similarities, 
including resistance to drugs and treatment with other reagents. Unlike normal 
stem cells, CSCs have also been found to exist in permanent cancer cell 
cultures. The hypothesis of a built-in CSC population in malignant tumours has 
given explanations why some cancers have been able to survive general cancer 
treatments and the disease has relapsed (Charafe-Jauffret et al 2009).  
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Neural stem cells (NSC) are multipotent cells found in the central nervous 
system, and found not only in embryos but throughout the life in the adult 
human and rodent brain.  NSC have been found even at the sites of pathology 
and damaged tissue in the brain. Different from CSC, these NSCs have the 
ability to form free-floating aggregates in vitro (Figure 2)(Corti et al 2006). These 
aggregates are called spheres or neurospheres. Spheres are not a pure 
population of stem cells because signs of differentiation have been found if 
spheres are grown in culture growth medium supplemented with serum 
(Mitrecic et al 2009). 
In recent years, identification and characterization of CSCs have taken a big 
leap forward, resulting in better understanding of the link between metastasis, 
stem cells and cancer survival (van der Hoogen et al 2010). 
              
Figure 2. Rat neurosphere (p350) (Invitrogen.com) and breast cancer stem cell 
(Celprogen) (p16) cultures. 
Rat NSCs and breast CSCs are captured with a phase-contrast microscope 
(Zeiss)(10x). 
 
3.1.1 Stem cell markers 
Common for the stem-like cells have been shown to be cell-surface 
glycoproteins CD44, CD133 and a specific enzyme called aldehyde 
dehydrogenase (ALDH). The CD44+ and CD133+ cells have been shown to 
have for example cancer-initiating properties and resistance to chemotherapy 
(Takaishi et al 2009, Ricardo et al 2011). ALDH+ cells have shown even more 
significant resistance to common cancer cell treatments and have been seen to 
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behave as biologically aggressive cells with the capacity to metastase (van den 
Hoogen et al 2010). 
Aldehyde dehydrogenase (ALDH) is an enzyme superfamily responsible for the 
oxidation of intracellular aldehydes. Enzymes have also been found to have an 
important role in the development of epithelial homeostasis and in drug 
resistance (van der Hoogen et al 2010).In a number of cancers the ALDH 
enzyme has been found to be deregulated, especially in stem-like cells and in 
endothelial progenitor cells as well as in epithelial stem cells. These findings 
have given rise to an assay of identification and isolation of cells with ALDH 
overexpression and possible stem-cell properties (Charafe-Jauffret et al 
2009).The high expression of ALDH in stem and stem-like cells was discovered 
when research targeted the resistance of cyclophosphamide and other 
alkylating reagent derivates in primitive hemapoetic stem cells (Sahovic et al 
1988). It was later found that this resistance was due to the high expression of 
ALDH enzyme in these cells.  
3.1.1.1 Aldefluor® Assay 
Aldefluor® Assay (ALDAGEN, STEMCELL technologies) is a protocol 
developed for identifying cells overexpressing ALDH enzyme 1 (ALDH1). 
ALDEFLUOR® fluorescent reagent contains a specific ALDH substrate which in 
viable cells is converted into fluorescent product; non-viable cells are unable to 
retain this reaction product inside the cell. The ALDH substrate is converted into 
a fluorescent product by this specific ALDH enzyme. Cells overexpressing 
ALDH enzyme can so be detected as ALDH bright (ALDHbr) because of the 
fluorescence (Stemcell technologies, 2008). ALDHbr detection is proportional to 
the ALDH enzyme present and further proportional to the cancer stem cell 
properties (Charafe-Jauffret et al 2009). The ALDEFLUOR® reagent is known 
to interact with the ALDH isoform 1A1 and probably also with 3A1 (Stemcell 
technologies, 2008). Other isoform interactions have not yet been determined.  
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3.2 Breast cancer cells 
The most common cancer among women is breast cancer. The disease occurs 
almost entirely in women, but also men can have it. About 10% of Finnish 
women are diagnosed with breast cancer at some point of their lives (Joensuu 
H et al 2007). Prevention of this cancer is not possible yet, but multiple methods 
have been developed to find tissue deformation early enough. The variations in 
morphologies and differences in metastatic behaviour and in the response to 
therapeutic treatments make breast cancers hard to treat.  
Nearly all breast cancers diagnosed are found as carcinomas. Epithelial tissue 
derived malignant tumours are called carcinomas, with the tendency of forming 
metastases. Adenocarcinomas are derived from the epithelia of glandular 
tissue; in this case the breast lobules and ducts (American Cancer Society, 
2011). The breast cancer cell lines and cell cultures used in this thesis were 
adenocarcinomas. 
3.3 Glioma cells 
A glioma is a tumor arising in the central nervous system, and usually as an 
infiltration to the brain tissue or spinal marrow. The tumor initiates in the glial 
cells, which are the non-neuronal cells forming the brain and spine supporting 
tissue. Glioblastoma initiates from the glial of primitive supporting tissue 
(Joensuu et al 2007). A primary brain tumor is not always malignant, but due to 
the closed position inside the skull and the slow regeneration of the nervous 
system, the consequences of a tumor in the brain might be more serious than 
those of a tumor in other parts of the body (IRSA, 2011). 
Annually about 650 brain tumors are diagnosed in Finland and 40% of these are 
gliomas (Joensuu et al 2007). Gliomas have the capacity to infiltrate into the 
brain tissue, which makes them hard to operate surgically. Brain tumors are 
graded from I to IV, depending on their malignancy, IV being the most 
aggressive (IRSA). The glioblastomas used in this study were graded IV (Figure 
3). Primary brain cancers rarely metastase to other parts of the body, but may 
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spread inside the brain and spine. In most cases of cancer, the healthy cells of 
the body are pushed aside by the uncontrolled cancer cell growth. In the case of 
glioma normal cells are destroyed due to the narrow space inside the skull. 
Glioblastoma tumours usually contain more than one type of cancer cells, which 
also makes them hard to treat: while some types of cancer cells are defeated, 
others continue dividing (IRSA).  
               
Figure 3.Glioblastoma A172 (p350) and U87 MG (p42) cell cultures. 
In this study cell lines were cultured on a plastic tissue culture dish (Corningen). 
Images of cell cultures were captured with a phase-contrast live-cell imaging 
instrument, IncuCyte (Essen Bioscience).  
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4 TRANSFECTION 
Transfection is a process of introducing foreign nucleic acids into eukaryotic 
cells. Numerous techniques can be utilized for the action of transfection, but all 
together the process has proved to be a powerful and essential tool for in vitro 
applications including studies of gene function and the modulation of gene 
expression as well as studies of protein production and intracellular signaling 
pathways (Prathees et al 2011). A therapeutic strategy such as tissue 
engineering and gene therapy also utilizes the technique. As a method, 
transfection can be carried out via chemical or physical procedures. 
The introduction of exogenous molecules, or genetic material like DNA or RNA, 
by transfection can be either a transient or a stable phenomenon, but for both 
the main idea is to deliberately modify the genome or the protein production of 
the targeted cell (Prathees et al 2011).   
Different transfection methods in principle can be categorized into two main 
groups, which are viral and non-viral methods. Viral transfection has very high 
transfection efficiencies, but since the handling and production of these viruses 
can be difficult, costly, and time consuming, viral transfection is not widely used 
(Hagemann et al 2005). 
Several approaches have been developed to overcome the limitations caused 
by the use of viruses. These so called non-viral methods include both chemical 
and physical processes. A transfection method combining both chemical and 
physical techniques is called nucleofection. 
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4.1 Chemical transfection 
The basic idea of chemical transfection is to neutralize the negatively charged 
exogenous molecule being introduced into the cells. The cell membrane is 
negatively charged as is the foreign molecule. The chemical reagents coat the 
molecule with cationic lipids, neutralizing or even creating an overall positive 
charge (Dean and Gasiorowski 2010). The foreign molecule is endocytosed into 
the cell.  
First generation chemical reagents used for the transfection of cultured 
mammalian cells were DEAE (diethlyamino ethanol) dextran and calcium 
phosphate based reagents. Both reagents are still widely used because of their 
low price and extremely easy use. The varying and low transfection efficiency 
together with the cytotoxicity of these reagents have limited their use (Dean and 
Gasiorowski 2011; Hagemann et al 2006). Competing chemicals have been on 
the market since the 1980s.  
Chemical transfection requires actively dividing cells (Brunner et al 2000). 
Foreign molecules are endocytosed into the cell where they travel either to the 
cell nuclei (DNA) or stay in the cytoplasm (RNA, proteins or antisense 
oligonucleotides) depending on where the site of action is (Watson et al 2008).  
4.1.1 Liposomal transfection 
The most widely used transfection method is the use of cationic liposomes as 
molecule carriers, a technique called lipofection (Dean and Gasiorowski 2011). 
Lipofection has been proven to efficiently deliver molecules from small 
oligonucleotides to entire proteins into the cell. This method also enables the 
transfection of cells that are too sensitive to calcium phosphate and DEAE 
based reagents (Felgner et al 1995). Both transient and permanent 
transfections can be obtained with the lipofection method and it can even be 
applied for in vivo transfections. 
Cationic lipids in the solution bind to the negatively charged exogenous 
molecule, together forming positively charged lipid–nucleic acid -complexes. 
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These complexes are able to bind onto the surface of the negatively charged 
cell membrane and be endocytosed due to the positive overall charge (da Cruz 
et al 2004). These cationic lipids, liposomes, are synthetic analogues of the cell 
membrane’s phospholipid bilayer.  
 
Figure 4. Lipofection. 
Exogenous material, DNA, is being 
introduced into the cell by lipofection . 
(Expertreviews, Cambridge University 
Press, 2003) 
 
 
 
4.1.2 Non-liposomal transfection 
The non-liposomal method is also based on endocytosis. Instead of using 
cationic lipids, non-liposomal transfection reagent contains polycationic 
polymers capable of forming micelles. Transfection usually takes place in an 
aqueous solution which enables the lipophilic heads of the polymer to enclose 
the exogenous material inside its micelle core with the hydrophobic tails. Non-
liposomal reagents are designed for cell lines that are too sensitive for 
liposome-based transfection. 
4.2 Physical transfection 
Physical techniques, like microinjection or electroporation, are simply based on 
a delivery of exogenous material through the membrane by physical force. 
Introducal can take place either in the cytoplasm or directly in the nucleus. 
Microinjection is basically a direct delivery of exogenous nucleic acid into the 
target cell’s nucleus. This particular technique has been used for example for 
transferring DNA into embryonic stem cells for producing transgenic organisms 
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(Bockamp et al 2002). The process is very effective but laborious and not an 
appropriate method for studies requiring a large number of transfected cells. 
Electroporation is a method based on the use of electrical pulses in order to 
disrupt the cell membrane. Perturbing causes transient pores on the membrane 
allowing foreign molecules the passage into the cell (Dean and Gasiorowski 
2011). Electroporation is a rather aggressive way of transfection for the animal 
cells (because of the missing cell wall) and often requires more cells than the 
chemical transfection procedures. 
4.3 Nucleofection 
A further alternative for the classic chemical and physical transfections is a 
method called nucleofection where exogenous material is being introduced into 
the cell via a method applying both chemical and physical techniques. With the 
Nucleofector technique, the foreign molecule is bound to proteins containing a 
nuclear localization signal in a cell–specific–solution. The formed complex is 
transferred into the cell via small pores on the cell membrane. Pores are formed 
by specific electrical shocks. As the molecule–protein -complex is being 
introduced straight into the nucleus of the cell; there is no need of cell division 
before obtaining the results of the recombinant protein expression. Because of 
the transfection is independent of cell division, protein expression can be seen 
already in four hours. (Hagemann et al 2006) 
The Nucleofector technology has been seen as a new and first efficient non-
viral transfection method for primary and stem cells and hard–to–transfect cell 
lines, mainly because of the straight nuclear introduction of the exogenous 
material. Nucleofection has shown better transfection efficiency than common 
lipofection reagents (Jacobsen et al 2006) and higher cell viability after 
transfection than with electroporation (Maasho et al 2004). 
In this work Amaxa 4D-Nucleofector™ device, X-unit was used for the 
nucleofection. 
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5 RNA INTERFERENCE 
RNA interference (RNAi) is an evolutionary conserved mechanism shared in 
eukaryotic cells. RNAi is a cellular process of RNA silencing resulting in 
reduced protein expression. RNAi phenomenon is found in fungi, plants, and in 
animals and it seems to be involved in a variety of regulatory and immune 
functions. In certain species, RNAi regulated gene activity is a normal defense 
mechanisms against viruses and the mobilization of transposable genetic 
elements (Pedraza-Fariña et al 2006). 
As a phenomenon, RNAi is triggered by a double-stranded RNA (dsRNA). This 
dsRNA suppresses the expression of a target protein by stimulating the 
sequence specific degradation of messenger RNA (mRNA). Messenger RNA is 
a mobile, single-stranded copy of a gene coding for the production of its specific 
protein. This copying is called transcription. Translation is the next step, where 
the mRNA is converted to its functional protein form (Joensuu et al 2007). RNAi 
occurs between the transcription and translation. RNAi mechanism involves a 
two-step process where ribonuclease, specifically called Dicer, first cleaves the 
dsRNA into small interfering RNA (siRNA) molecules. The small molecules 
generated are about 20 nucleotides long. Second, these siRNA’s are 
incorporated into an RNAi targeting complex called RISC (RNA-induced 
silencing complex) that results in a base-pair-dependent mRNA cleavage and 
decreased protein expression (Figure 5). Since the impact is targeted towards 
mRNA instead of the DNA, the blockage of protein synthesis is reversible 
(Pedraza-Fariña et al 2006). 
The phenomenon of RNAi was first discovered in plants at the start of the 
nineties, but theory for the observations was provided in 1998 when dsRNA was 
found to be the one inhibiting the expression of its homologous RNA. The 
observation was first found in a nematode worm, Caenorhabditis elegans (Fire 
et al 1998). Findings of the long dsRNA molecule, which induced nonspecific 
knockdown of a gene, expanded the experimental use of RNAi to mammalian 
cell associated research. It was a couple of years later when short dsRNA 
molecules were found to downregulate specific genes (Krueger et al 2007). 
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Today, RNAi is considered as an important tool for the study of gene expression 
and a tool for the analysis of molecular mechanisms of various diseases. 
Degradation of the mRNA results in the interference of the protein production 
and further to the function of the whole cell. The phenomenon is, in other words, 
used for studying the influence of certain protein on the cell function. In future, 
RNAi could enable the usage of dsRNA as a therapeutic molecule. 
 
 
     
 
Figure 5. RNA interference.  
The phenomenon of RNAi occurring in mammalian cells. Endogenous microRNAs 
(miRNA) are exported from the nucleus to the cytoplasm. Small interfering RNAs 
(siRNA) being integrated into the RNA induced silencing complex (RISC) results to 
the degradation of messenger RNA (mRNA) and reduced protein expression.  
(Watson et al 2008, pp 642) 
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5.1 RNAi and Cancer 
RNAi has already made its way as a new tool in the analysis of molecular 
mechanisms for various diseases. Cancer is no exception. RNAi has made it 
possible to functionally identify genes that are involved in cancer initiation and 
new cancer-relevant genes have been found.  
The use of RNAi has encouraged the development of a new technology for 
gene therapy applications in the treatment of cancers. Gene specific silencing 
has allowed systematic screens for new drugs, and the effect of already existing 
drugs could have been enhanced. RNAi has enabled silencing to occur with 
high specificity and more efficiently than with any other technique before 
(Thakur 2003). 
Instead of transfecting big dsRNA molecules in to the cells, chemically 
engineered siRNA’s enable targeting the specific genes. This has resulted in 
identification of proteins that are crucial for cell viability (Manoharan 2004; 
Krueger et al 2007). 
Today, there are lots of hopes and promises for using siRNAs as drugs directed 
directly and only into the cancer cells. RNAi protein silencing has been used 
and shown good promises in cell cultures and in animal models, which 
encourage siRNA based reagents for clinical usage to treat cancer as well as 
other diseases. SiRNA can be transfected directly into the cells or organs, but 
stability in the blood stream, the duration of the effect and the delivery 
techniques are still quite big questions before RNAi-based cancer therapy can 
be used (Ozpolat et al 2009). 
  
23 
 
6 MATERIALS AND METHODS 
6.1 Stem Cells and Cancer Cell Cultures 
Breast Epithelial Cell Culture and Breast Cancer Stem Cells were purchased 
from the Celprogen (St San Pedro, CA). Glioma Cancer Stem Cell Culture 
(CSC 1904) was obtained from Helsinki University (Sariola/ Laura Kerosuo) and 
brain glioblastomas A-172 and U-87 MG from the ECACC (European Collection 
of Cell Cultures). Breast adenocarcinoma cell culture MCF 7 was purchased 
from  the ICLC (Interlab Cell Line Collection), ductal breast carcinoma BT-474 
and breast mammary gland adenocarcinoma (metastatic site) SK-BR-3 from the 
LGC Standards (Laboratory of Government Chemist). Prostate, lymph node 
carcinoma LNCaP, which was used as a control, was obtained from the ATCC 
(American Type Culture Collection).  
Cell Line Characteristics  
Epithelial Breast Stem Cells are Nestin, estrogen receptor (ER) and 
progesterone receptor (PR) positive. Breast Cancer Stem Cells are HER2 
receptor positive but ER and PR negative (double negative). (Certificate of 
Analysis, Celprogen; Sharma et al, Celprogen) 
Thawing the Cells 
All the cells and cell lines were thawed by warming the frozen ampoules in 37 
°C for 1-2 minutes. Vials were submerged only partially and swirled constantly 
in the water bath. Thawed cells were immediately transferred into a 15 ml sterile 
centrifuge tube with 5 ml of fresh prewarmed growth media. Cells were 
centrifuged (Eppendorf AG, Hamburg, Germany) to a soft pellet at 100 x g for 5 
minutes. Supernatant was removed and cells were resuspended into 10 ml of 
fresh prewarmed media. Cells were cultured on an Ø 10 cm tissue culturing 
dish (Corning) or pre-coated T75 flasks (Celprogen cells; Celprogen flasks). All 
complete growth media - receipts are listed in Appendix 1.  
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Cell Seeding and Subculturing 
Cells were subcultured after reaching 70-80% confluency. Cell monolayers 
were washed with 1 x PBS (Dulbecco’s Phosphate Buffered Saline, Sigma-
Aldrich, St. Louis, MO) and trypsinised with 1 x trypsin-EDTA (ethylene-
diamine-tetraacetic acid, stock 10 x, Sigma-Aldrich, St. Louis, MO) diluted with 
PBS for 1x concentration. Trypsinized cells were subcultured at a ratio of 1:2 to 
1:10, depending on the next assay the cells were used for. Cells were incubated 
at 37 °C and 5% CO2 cell incubator (HERAcell 240i, Thermo Scientific). Media 
for the Celprogen cells was changed every 24 hours, 2-3 times per week for the 
other cell cultures. CSC 1904 cells were cultured on ultra-low attachment plates 
(Corning, NY). 
Freezing media for the different cell cultures was the growth medium (listed in 
Appendix 1) supplemented with 10% of DMSO (Dimethyl sulfoxide, Sigma-
Aldrich). Cells were first trypsinised as usual and counted by using the Bürker 
cell counting chamber. 2-5 million cells were counted for 1 ml of freezing media 
into one freezing ampoule (Nalgene, Thermo Scientific, Rochester, NY). 
Sufficient number of cells was centrifuged at 100 x g for 5 minutes. Obtained 
cell pellet was resuspended to the precooled freezing media and transferred 
into -80°C freezer for at least 24 hours before removing the ampoules into -150 
°C freezer for long term storage.  
6.2 High Throughput (HT) Transfection 
Reverse transfection protocol was used since this technique is functional for 
HTS screenings. Briefly, siRNAs were pipetted into the wells of 384-well plates 
and covered by the transfection reagents. After one hour incubation at room 
temperature (RT), cells were cultured on top of the siRNA-reagent -complexes. 
After 72 hour incubation transfection efficiency was determined by measuring 
the effect of cell death control to the effect of cell proliferation with CellTiter-
Glo® (CTG)-assay. In order to maintain the transfection conditions stable, cells 
were passaged 2-3 days prior transfection and never exceeding 85% 
confluency. 
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6.2.1 Transfection Reagents 
Eight different commercial transfection reagents were tested. Reagents were 
chosen for their ready-to-use 384-protocols, or because of the expectations for 
efficient primary and stem cells transfection or just because of the economic 
point-of-view. The efficiency and toxicity values of transfections were compared 
with the results from siLentFect™ transfection. Reagents tested were HiperFect 
HTS (Qiagen), INTERFERin-HTS (Polyplus), Lipofectamine™ (Life 
Technologies), X-tremeGENE siRNA (Roche), RNAi MAX (Invitrogen), 
DharmaFect1 (Thermo Scientific), TrueFect-Lipo™ (United Biosystems) and 
PromoFectin (PromoKine). The latter reagent was non-lipid based. All 
transfection reagents and volume ranges per transfection recommended by the 
manufacturer are listed below (Table 1.). Two new batches of siLentFect™ 
were also tested. 
Table 1. Commercial transfection reagents tested with six different cell cultures. 
Reagent Manufacturer Recommended volume range for 
siRNA transfection (µl) in 384-format 
siLentFect Bio-Rad 0,013 – 0,1 
INTERFERin™-HTS  Polyplus 0,05 – 0,1 
True-Fect Lipo  United Biosystems 0,09 – 0,18 
HiPerFect Qiagen 0,01 – 0,3 
x-tremeGENE Roche 0,03 – 1,0 
PromoFectin PromoKine 0,013 – 0,13 
RNAi MAX Invitrogen 0,025 – 0,075 
DharmaFect 1 Thermo Scientific 0,013 – 0,13 
 
Scrambled target sequence was used as a negative siRNA control (siNEG) and 
cell death siRNA as a positive control. AllStars negative control (Qiagen) is a 
nonsilencing siRNA where non-specific effects are controlled. AllStars cell death 
control siRNA (Qiagen) targets universally expressed human genes, which are 
essential for cell survival. With cell death, the transfection efficiency can be 
quickly estimated. Other siRNA’s used were siPLK, siKIF, siERBB and 
siSTARD (Qiagen) (Table 2.). 
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Table 2. SiRNA’s used in the transfections 
siRNA Target  Sequence 
PLK1_7  polo-like kinase 1_7 (Drosophila) 5’ CGC GGG CAA GAT TGT GCC TAA 3’ 
KIF11_7 kinesin family member 11_7 5’ GCC GAT AAG ATA GAA GAT CAA 3’ 
ERBB2_15 receptor tyrosine-protein kinase 
erbB2 precursor 
5’ CAC GTT TGA GTC CAT GCC CAA 3’ 
STARD3_2 stAr-related lipid transfer protein 5’ CAC CTT TGT CTG GAT TCT TAA 3’ 
 
6.2.2 Transfection protocol 
The first sets of transfections were carried out by following the manufacturers’ 
recommended volume ranges for the reagent. Each reagent was first tested 
with 3 different volumes: median from the recommended, one below the 
median, and one above.  
5 µl of 165nM siRNA was pipetted into the wells of 384-well plate (Corning). 
Each siRNA was pipetted as four replicates (quadruplicates). Transfection 
reagents were first diluted with Opti-MEM® I (Gibco®, Invitrogen, Paisley, UK) 
or with filtered nuclease free water (Ambion), depending on whether the reagent 
was lipid or non-lipid based. Reagent dilutions were mixed by pipetting and let 
to incubate in room temperature (RT) for 10-15mins. 10 µl of the reagent 
dilution was pipetted on top of the siRNA and centrifuged at 100 x g for 1 min. 
Reagent - siRNA complex was incubated at RT for 60 mins. While incubating, 
cells were detached with 1 x trypsin-EDTA and trypsinization was inactivated 
with prewarmed growth media. Cell suspension was centrifuged at 100 x g for 5 
mins, supernatant removed and the cell pellet resuspended into 5 ml of growth 
media.  Cell number was determined with Bürker Chamber. Depending on the 
cell line, 1500 – 2000 cells / 35 µl media / well were recovered. After the 
incubation, cells were pipetted on top of the siRNA – reagent complexes and 
centrifuged at 100 x g for 1 min. Transfection was incubated in 37°C, 5% CO2 
cell incubator for 72 hours. 
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6.2.3 CellTiter-Glo® (CTG) –measurement 
CTG® -measurement is a luminescent cell viability assay, where the number of 
viable cells in the sample is determined. Active, viable cells use ATP as their 
energy supplier between anabolic and catabolic reactions. For this reason the 
presence of ATP can be used as an indicator of metabolically active cells 
(solunetti, 2012). Addition of CTG® reagent results in cell lysis, releasing the 
ATP and enzyme called luciferase to interact with the compounds in the CTG® 
reagent forming a luminescence signal. The signal detected is proportional to 
the concentration of ATP present and the amount of ATP is proportional to the 
number of viable cells present (Promega, information sheet 08/2011). After 72 
hour incubation of the siRNA treated cells, the cell viability was determined by 
CTG® and the luminescence detected by multilabel reader. CTG® reagent was 
first let to thaw to room temperature. For the 384-well plate 25 µl of this reagent 
was pipetted per well, without removing the cell culture media. For induction, 
the cell lysis sample plate was left on the shaker for 30 mins at RT with speed 
of 175 rpm (Heidolph Unimax 1010). After mixing, the luminescence was 
recorded with a multilabel reader (Wallac Envision, PerkinElmer). 
6.2.4 Optimization 
Optimization of the transfection reagent volume was done according to the 
results gained from the CTG® measurements. The effects of siPLK, siKIF, 
siERBB2, and siSTAD3 and cell death were compared to the siNEG in order to 
determine the transfection efficiencies. Overall cell viability was controlled by 
samples of “cells only”.  
6.3 Nucleofection 
The Nucleofector technique developed by Amaxa is based on the variation 
between the electrical pulse programs and the cell-type specific solution. The 
manufacturer provides optimization protocols for both cell lines and primary 
cells. Here, transfections were done with 4D- Nucleofector® X unit (Amaxa, 
Lonza Cologne, GmbH) for cells in suspension. For the cell lines, there were 3 
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different Nucleofector® X solutions (Cell Line Kit SE, SF, and SG) and five for 
primary cells (Cell Line Kit P1 to P5). Here, Cell Line Kit SF and SG were used 
for the BT 474 cell line and Cell Line Kit P3 for cancer stem cells and breast 
epithelial cell culture. Cell-specific solutions were suggested by a representative 
from Lonza. The electrical parameters of the nucleofector device were 
optimized for each cell culture. The correct electric pulse for each sample was 
chosen by first transfecting pmaxGFP® vector (Amaxa, Lonza Cologne, AG) 
into the cells. Analysis of the transfection efficiency and cell viability determined 
which programs to choose for following siRNA transfection. Optimization and 
siRNA transfection protocols are described next. All nucleofections were carried 
out in a 16-well Nucleocuvette® Strip. 
6.3.1 Optimization – Nucleofection of pmaxGFP® Vector 
Cells were subcultured 2-3 days before the nucleofection, depending on the cell 
culture. The slow growing cell line, BT 474 for example, was passaged 3 days 
prior. Cells were let to grow to about 80% confluency. Next, cells were 
trypsinized with 1x Trypsin-EDTA and suspended with cell growth culture 
media. 5 x 105  cells per well were centrifuged at  90 x g for 10mins in room 
temperature, and  cell pellet resuspended with 360 µl of Nucleofector® Solution 
where supplement (supplement 1, Amaxa, Cologne, AG) and 5 µl of 
pmaxGFP® vector was added before the use. 150 µl of Supplement™ 1 was 
mixed with 675 µl of the Nucleofector® solution. Cell line kit P3 was used for the 
stem cancer and epithelial cells, cell line kits SF and SG for the BT 474.  20 µl 
of the cell – solution mix was pipetted into each of the 16 wells on the strip. 
Amaxa 4D-Nucleofector® Optimization Protocol was followed when setting up 
the nucleofector programs (Optimization Protocol for Primary Mammalian 
Neurons and Protocol for Primary Breast Cancer Cells and Protocol for Cell 
Lines, Amaxa). Nucleocuvette® was placed into the X-unit of the device and ran 
through selected programs. Subsequently, 80 µl of prewarmed low-calcium 
RPMI-1640 (Sigma-Aldrich) was pipetted into the wells and incubated for 5 mins 
at room temperature before plating the cells on 12-well culture plates (Corning) 
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with 1 ml of prewarmed cell growth media. Cells were incubated in 37°C, 5% 
CO2 IncuCyte FLR (Essen Instrument) for 24 hours. 
6.3.2 Cell Viability and Transfection Efficiency 
After 24 hours of incubation cells were trypsinized, centrifuged briefly and 
resuspended with 20 µl of PBS diluted, 0.4 % trypan blue solution (Sigma-
Aldrich), dilution 1:1. Cell viability and the GFP+ (green fluorescent protein) cell 
number were determined with Cellometer™ (Nexcelom, Bioscience). According 
to the results and optimization guideline of nucleofection conditions (Figure 13.) 
programs for siRNA transfections were chosen. 
6.3.3 Nucleofection of siRNA 
SiRNA’s used in nucleofection are listed previously, see table 2 page 25.  
Cells were first harvested by trypsinization and the required cell number, 5x105 
per well, was centrifuged. Cell pellet was resuspended with 360 µl of the cell 
specific Nucleofector® solution. 90 µl of the cell suspension was pipetted into 
four eppendorf tubes. 100 nM of each of the four siRNA was added into 
eppendorfs. P3 Nucleofector® solution was used for the stem cancer and 
epithelial cells, and SF Nucleofector® solution for the BT 474 cell line. 20 µl of 
the cell – siRNA mix was pipetted into the 16 wells of the cuvette and ran 
through the optimized Nucleofector® program. 80 µl of the low-calcium cell 
culture medium RPMI-1640 was added into the wells and let to incubate for 5 
minutes in room temperature. Subsequently, cells were plated on a 12-well 
plate and incubated in 37°C, 5% CO2 phase-contrast IncuCyte (Essen 
Instrument) for 72 hours.  
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6.4 Aldefluor® Assay 
Aldefluor® Assay was started by activating the specific ALDEFLUOR® 
substrate. Activation was done by following the product information sheet 
provided with the ALDEFLUOR® kit. Aldefluor stained cells have earlier been 
detected by a fluorescence-activated cell sorting device (FACS) that is a 
specialized flow cytometer (Ketola et al 2011; Charafe-Jauffret et al 2009). In 
here, aldefluor stained cells were detected by a multilable reader and 
fluorescent microscopy. 
6.4.1 Determination of ALDH activity  
384-well Format, Adherent Cells 
Aldefluor® assay was first performed by using a previously established 
manufacturer’s protocol, downscaled to 384-well format (Ketola et al 2010). 
ALDH activity determination was done with breast cancer stem cells, breast 
epithelial cells and LNCaP prostate carcinoma cells. Briefly, 2,000 cells per well 
plated with 35 µl of media in 384-well plates with replicates of 8 and incubated 
overnight in 37°C. Salinomycin (Sigma-Aldrich) and cyclopamine (Sigma-
Aldrich) were added in 15 µl to final concentration of 1 µmol/L in 50 µl. DMSO 
(Sigma-Aldrich) was added as a control to a final concentration of 1 ‰. 
Samples were incubated for 48 hours in 37°C. After incubation, medium was 
removed and cells washed with 20 µl of PBS. 10 µl of Aldefluor or Aldefluor with 
DEAB (ALDH inhibitor diethlyaminobenzaldehyde) was pipetted onto the cells 
and incubated at 37°C for 30 minutes. Solutions were removed, cells washed 
with 20 µl of PBS and 20 µl of assay buffer was added into each well. The 
fluorometric signal was determined.  
Cell In Suspension  
Second set of ALDH activity determination was done with breast cancer stem 
cells and SK-BR-3 breast carcinoma cells. Cells were grown to about 70% 
confluency before harvesting by trypsinization. 1 x 106 cells/ml were centrifuged 
at 200 x g for 7 mins. Supernatant was removed.  
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2,5 µl of activated ALDEFLUOR® substrate was added to 500 µl of assay 
buffer. 250 µl of this solution was placed into another eppendorf called “control”, 
where 5 µl of DEAB was added. Obtained cell pellets were resuspended into 
ALDH positive solution and negative control solution and incubated in 37°C 
water bath for 30 minutes. Aldefluor substrate solution was removed by 
centrifuging at 300 x g for 5 minutes at 4°C. Supernatant was removed and 
pellets resuspended with 125  µl of ice cold assay buffer. Samples were placed 
and kept on ice. From 20 through to 60 µl of sample was pipetted to a 384 well 
plate (black, Corning) for fluorometric signal determination. 
6.4.2 Multilabel Reader and Fluorescence Microscope 
The fluorometric signal was determined with Envision 2100 Multilabel Reader. 
Program used for the signal detection was with a scanning program (excitation 
485 nm, emission 535 nm). In between of the detection programs, sample plate 
was placed on ice in order to prevent the efflux and thus saving the 
fluorescence stain in the cells. 
20 µl of the sample was pipetted onto a glass microscopic slide. Samples were 
visualized by a fluorescent microscope (eCFP and eGFP filters)(Zeiss) for 
further demonstrating the ALDH expression. 
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7 RESULTS 
Good transfection results are never unambiguous; transfection efficacy and the 
cytotoxic effect need to be considered. The raw results for transfection efficacy 
were gained by comparing siRNA transfection samples against cells only. The 
cytotoxicity of the transfection reagents was observed with the siNEG control. 
Other factors influencing the selection of the best transfection reagent were the 
simplicity of the protocol, the volume of the reagent needed for the experiment, 
and the financial point-of-view. 
7.1 Chemical Transfection 
After 72-hour incubation, the effect of siRNA transfection was determined by 
changes in cell proliferation. The results were achieved by CTG assay and an 
Envision Multilabel reader. The toxicity of the reagent and the transfection 
efficiencies were determined by the cell viability. All the cells were transfected 
with eight different commercial reagents (table 1). Here, only the best 
transfection results are shown.  
MCF-7 cell culture 
An MCF-7 cell culture was used as a starting control for the transfection reagent 
testing. MCF-7 has previously shown to be easy to transfect with SiLentFect. 
HiPerFect, with a volume of 0.05 l per well (total volume 50 l), showed similar 
efficacy results as achieved with SiLentFect, the volume being 0.09 l per well 
(Figure 6). SiKIF transfection was slightly more efficient with HiPerFect, but the 
SiLentFect siPLK and cell death siRNA values were better (Table 3) and this 
reagent showed lower reagent toxicity (Figure 7). The most efficient reagent 
however was a novel TrueFect-Lipo reagent that has not previously been used 
at VTT for HT transfections.  
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Figure 6. MCF-7 transfection results.  
 MCF-7 cells were transfected with eight different commercial transfection reagents. 
The five best transfection values were obtained with SiLentFect, TrueFect, x-
TremeGene and HiPerFect HTS. From these five reagents, True-Fect shows to be the 
most efficient reagent for transfecting MCF-7 cells with over 80% transfection efficacy. 
Relatively good transfection results, over 70%, were obtained with SilentFect (#2281A). 
Effect on cell proliferation is shown relative to cells only (100%). 
Table 3. MCF-7 transfection results with the highest transfection efficiencies. 
Transfection efficiency is shown relative to negative control (siNEG). 
siRNA TrueFect-Lipo 
 
[0.02 µl] 
SiLentFect 
#2281A 
[0.09 µl] 
siNEG 100 % 100 % 
siPLK  102 % 95 % 
siKIF 50 % 67 % 
Cell Death 16 % 27 % 
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Figure 7. MCF-7 transfection results with HiPerFect and SiLentFect  
The best two transfection results were achieved with TrueFect-Lipo (0.2 l) and 
SiLentFect #2281A (0.09l). The efficacy of the transfections (shown as the effect 
compared to siNEG) and cytotoxicy (shown as the effect of siNEG compared to cells 
only) of the reagents are compared with each other. Better transfection efficacy was 
obtained with TrueFect-Lipo (84%), but neither of the reagents showed high 
cytotoxicity. 
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BT-474 cell culture 
Transfection reagent TrueFect-Lipo showed also the best efficiency for BT-474 
transfection (Figure 8).  With a volume of 0.08 l per well, approximately 30% 
transfection efficacy was obtained with TrueFect-Lipo. SiRNA cell death did not 
show high specificity, since the effect on the cell proliferation was similar 
between siPLK, siKIF and siRNA cell death transfected cells (Table 4). BT-474 
cells are considered difficult to transfect, with sensitivity to toxic effects of the 
transfection reagents (Figure 9). 
 
Figure 8. BT-474 transfection results.  
BT-474 cells were transfected with eight different commercial transfection reagents. Of 
these reagents, only TrueFect and siLentFect showed even a slight efficacy. Other 
reagents were either cytotoxic or showed no transfection effect at all. Effect on cell 
proliferation is shown relative to cells only (100%). 
Table 4. BT-474 transfection results with the highest transfection efficiencies. 
Transfection efficacy is shown relative to negative control (siNEG). In case of 
SiLentFect the strong toxic effects should be noted. 
siRNA TrueFect-Lipo 
 
[0.08 µl] 
SiLentFect 
#2281A 
[0.06 µl] 
siNEG 100 % 100 % 
siPLK  75 % 65 % 
siKIF 71 % 82 % 
Cell Death 67 % 53 % 
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The transfection of BT-474 cells was concluded as non-efficient, mainly 
because of strong cytotoxic effect of all tested reagents. 
 
Figure 9. BT-474 transfection results with TrueFect  
TrueFect-Lipo with a volume of 0.08 l showed the best cell survival and transfection 
efficacy, approximately 30%, for the BT-474 cell culture. The efficacy of the 
transfections (shown as the effect compared to siNEG) and cytotoxicy (shown as the 
effect of siNEG compared to cells only) of the reagents are compared with each other. 
  
86% 
64% 61% 58% 
100% 
75% 71% 67% 
siNEG siPLK siKIF cell death
TrueFect 0.08 µl 
Effect compared to cells only
Effect compared to siNEG
37 
 
Breast Epithelial Cell Culture 
In small concentrations, 0.02 to 0.04 l, SiLentFect #2281A and HiPerFect 
showed the best transfection efficacy for the breast epithelial cells with 
approximately 30% of transfected cells (Figure 10). SiRNA cell death was seen 
to have no targeted effect, while siKIF showed more cell growth inhibiting factor 
(Table 5). Both of these reagents showed cytotoxicity, even at small 
concentrations (Figure 11). 
 
 
 
Figure 10. Breast epithelial cell transfection results 
Breast epithelial cells were transfected with eight different commercial transfection 
reagents. Of these eight reagents, siLentFect (#2281A) and HiPerFect showed some 
efficacy at small concentrations, approximately 30 % transfected cells. Higher 
concentrations of reagents were cytotoxic for the epithelial cells. Cell proliferation is 
relative to cells only (100%). 
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Table 5. Breast Epithelial Cell transfection results with the highest transfection 
efficiencies. 
Transfection efficacy is shown relative to negative control (siNEG). 
siRNA siLentFect  
#2281A 
[0.02 µl] 
HiPerFect 
 
[0.04 µl] 
siNEG 100 % 100 % 
siPLK  89 % 89 % 
siKIF 65 % 71 % 
Cell Death 76 % 75 % 
 
 
 
Figure 11. Breast epithelial cell transfection results with SiLentFect and HiPerFect 
Breast Epithelial cells showed sensitivity against the transfection reagents, even with 
small concentrations cell viability was shown to be less than 75 %. The efficacy of the 
transfections (shown as the effect compared to siNEG) and cytotoxicy (shown as the 
effect of siNEG compared to cells only) of the reagents are compared with each other. 
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Breast cancer stem cells 
The transfection of Breast CSCs showed promising results with SiLentFect 
#2281A and HiPerFect where more than 50% transfection efficacy was 
obtained (Figure 12, Table 6). SiLentFect showed some cytotoxicity, but 
showed good transfection efficacy even with small concentrations (Figure 13). 
 
 
Figure 12. Breast CSC transfection results. 
Breast Cancer Stem Cells were transfected with eight different commercial transfection 
reagents. From these reagents SiLentFect #2281A showed the best transfection 
efficiency. HiPerFect also showed high cell viability and but not good transfection 
results. Effect on cell proliferation is relative to cells only (100%). 
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Table 6. Breast CSC transfection results with the highest transfection efficiencies.  
The transfection efficiency is shown relative to negative control (siNEG).  
siRNA siLentFect  
#2281A 
[0.02 µl] 
siLentFect 
#2281A 
[0.04 µl] 
TrueFect 
 
 [0.1 µl] 
siNEG 100 % 100 % 100 % 
siPLK  88 % 56 % 89 % 
siKIF 77 % 69 % 76 % 
Cell Death 73 % 42 % 76 % 
 
 
Figure 13. Breast CSC transfection results with SiLentFect 
SiLentFect #2281A, with a volume of 0.04 l, showed the best cell survival and 
transfection efficiency, approximately 60%, for the breast CSC cell culture. The efficacy 
of the transfections (shown as the effect compared to siNEG) and cytotoxicy (shown as 
the effect of siNEG compared to cells only) of the reagents are compared with each 
other. 
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U-87 MG cell culture 
Transfection of U-87 MG was shown to be most efficient with SiLentFect 
#2281A and x-tremeGENE (Figure 14.) reagents. The highest transfection 
efficacy was achieved with SiLentFect, with over 80% transfected cells (Table 
6). High transfection efficacy was achieved with both of these reagents without 
strong cytotoxicity (Figure 15). SiPLK was not used when testing SiLentFect 
#2281A reagent. 
 
 
Figure 14. U-87 MG transfection results. 
U-87 MG cells were transfected with eight different commercial transfection reagents. 
Some of these reagents were only used for transfecting siKIF, siNEG and siRNA cell 
death. The best transfection efficiency was obtained with SiLentFect #2281A with over 
80% transfected cells and x-tremeGENE with approximately 50 % transfected cells. 
Effect on cell proliferation is relative to cells only (100%).   
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Table 7. U-87 MG transfection results with highest transfection efficiencies. 
The transfection efficiency is shown relative to negative control (siNEG). 
siRNA siLentFect  
#2281A 
[0.07 µl] 
Interferin 
 
[0.04 µl] 
x-tremeGENE 
 
 [0.1 µl] 
siNEG 100 % 100 % 100 % 
siPLK  n/a % 93 % 66 % 
siKIF 61 % 76 % 85 % 
Cell Death 14 % 50 % 45 % 
  
 
Figure 15. U-87 MG transfection results with SiLentFect and X-tremeGENE 
SiLentFect, with a volume of 0.07l, showed the highest transfection efficacy than other 
reagents. With SiLentFect more the 85 % of the cells were transfected, and cell viability 
was more than 90 %. Transfection efficacy with X-tremeGENE was also promising with 
more than 60 % transfected cells. The efficacy of the transfections (shown as the effect 
compared to siNEG) and cytotoxicy (shown as the effect of siNEG compared to cells 
only) of the reagents are compared with each other. 
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A-172 cell culture 
Transfection of the A-172 cells showed good results with the HiPerFect and 
SiLentFect #2281A reagents, with approximately 90 % transfection efficacy 
(Figure 16 and Table 8). 
 
 
Figure 16. A-172 transfection results 
A-174 cells were transfected with the eight different commercial transfection reagents. 
Some of the reagents were not used for transfecting siPLK. The best transfection 
efficacy was achieved with HiPerFect. SiLentFect #2281A, with a volume of 0.07 l, 
was also suggesting good transfection results with better cell viability than with 
HiPerFect. Cell proliferation is relative to cells only (100%). 
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Table 8. A-172 transfection results with highest transfection efficiencies.  
The transfection efficiency is shown relative to negative control (siNEG). 
siRNA siLentFect  
#2281A 
[0.07µl] 
HiPerFect 
 
[0.025 µl] 
SiLentFect 
#2279A 
[0.07µl] 
siNEG 100 % 100 % 100 % 
siPLK  58 % n/a % n/a % 
siKIF 62 % 60 % 45 % 
Cell Death 6 % 3 % 5 % 
 
 
Figure 17. A-172 transfection results with HiPerFect 
HiPerFect showed the best transfection results with a volume of 0.025 l. SiNEG 
showed better cell survival than the cells only, which may have given unreliable results 
on the expense of efficacy percentage. The efficacy of the transfections (shown as the 
effect compared to siNEG) and cytotoxicy (shown as the effect of siNEG compared to 
cells only) of the reagents are compared with each other 
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Glioma CSC 1904 cells 
Transfection of the glioma CSC 1904 cells was shown to be non-efficient. 
Reagents showed to be toxic with higher concentrations, and non-effective 
when higher cell viability was achieved (Figure 18)(Table 9). TrueFect-Lipo 
showed an effect but also high cytotoxicity with 0,1 l per well. Further test 
between 0,06 and 0,1l may still be beneficial. 
 
 
Figure 18. Glioma CSC 1904 transfection results 
Glioma CSC 1904 cells were transfected with the eight different commercial 
transfection reagents. All the reagents showed either no effect or cytotoxicity values 
were too high, except for TrueFect-Lipo where further testing may still be beneficial. 
Cell proliferation is relative to cells only (100%). 
Table 9. CSC 1904 transfection results. 
The transfection efficiency is shown relative to negative control (siNEG). 
siRNA siLentFect  
#2281A 
[0.06/µl] 
PromoFectin 
 
[0.4/ µl] 
TrueFect 
 
[0.1/µl] 
siNEG 100 % 100 % 100 % 
siPLK  53 % 86 % 53 % 
siKIF 34 % 98 % 34 % 
Cell Death 8 % 87 % 8 % 
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7.2 Nucleofection 
According to the results gained from the pmaxGFP™ nucleofection (Tables 10 
to 13), two to four programs were selected for the second nucleofection (siRNA 
transfection). Nucleofection efficacy was determined by the cell viability and the 
number of cells with green fluorescence protein (GFP-positive) in the 
optimization step. By following the “Optimization of Nucleofection™ Conditions” 
(Figure 19.) the Nucleofector programs were reselected for gaining either an 
increase in the cell viability or in the transfection efficiency. 
 
Figure 19. Optimization of Nucleofection™ Conditions 
A short guideline for the program optimization when an increase of the transfection 
efficiency or cell viability is needed (Lonza, Amaxa). 15 programs in the middle-section 
(Best program(s)) are set as default programs in optimization. According to the results 
of each program, the viability can be increased by selecting a pulse program from the 
left hand side or right hand side in order to increase the efficiency. 
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Glioma CSC 1904  
Programs selected for the siRNA nucleofection of CSC 1904 cell culture were 
CA 137, CA 158, EN 138, and EH 118, since the best efficacy and cell viability 
were achieved with these programs (Table 10). After the 3-day-incubation, 
nucleofection efficacy was determined by the confluency results gained from the 
phase-contrast IncuCyte. Program EN 138 with the Cell Line Kit P3 gave the 
best transfection results, with up to 50% efficacy (Figure 20). SiRNA 
transfection can be seen as a transient, since after 60 hour-incubation the cell 
growth seems to emerge even with siRNA cell death nucleofected cells; the cell 
growth with siNEG and siPLK seem to reach the confluency after 70-hour-
incubation, which is seen as stabilized cell number. 
Table 10. Results of CSC 1904 pmaxGFP™ nucleofection. 
Results gained from the 16-well program format. Highest efficiencies with best cell 
viabilities were CA 137, CA 158, EN 138 and EH 118. 
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Figure 20. Nucleofection of  CSC 1904 with EN 138 program and Cell Line Kit P3.  
CSC 1904 nucleofection results after 3-day-incubation.Confluency values are scaled to 
0% confluency as a starting point. 
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Breast epithelial and CSC 
PmaxGFP™ nucleofection results were obtained from the FLR IncuCyte 
detections; cell viability from the confluency and GFP-positive cell number from 
the fluorescence mean. For the epithelial cells best programs were DS 138 and 
En 104 with both more the 96 % cell viability and about 20 % transfection 
efficacy (Table 11). These two programs were selected for the siRNA 
transfection, where DS 138 showed better results (Figure 22). Nucleofection 
efficacy was determined by the confluency values achieved by phase-contrast 
IncuCyte. SiRNA showed to be more stable for epithelial cells than for glioma 
CSCs (Figure 20); even after 80-hour-incubation the siRNA cell death 
nucleofected cells were with confluency less than 10 %. 
 
 
 
 
 
Figure 21. pmax™GFP nucleofected breast epithelial cells and CSCs. 
Cells at 70 hour time point at the IncuCyte FLR (Essen Instrument). a) breast epithelial 
cells pictured with fluorescent filter, b) breast epithelial cells from the same spot with 
the phase contrast. Picture c) Breast CSCs with fluorescent filter, and d) Breast CSC 
with phase contrast. Bright GFP-fluorescence showed good nucleofection result. 
Table 11. Results of Breast Epithelial cell pmaxGFP™ nucleofection. 
Highest transfection efficiency with best cell viability was achieved with DS 138 and En 
104 programs and Cell Line Kit P3. 
 
      a                 b               c                      d 
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Figure 22. Nucleofection of Breast Epithelial cells.  
Breast Epithelial cell nucleofection results after the 3-day-incubation. The best 
nucleofection efficacy values, more than 50%, were obtained with the nucleofector 
program DS 138 and the primary cell line kit P3. Confluency value is relative to 0% 
confluency as a starting point.  
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Breast CSC Nucleofector showed the best results with programs CM 138 and 
DS 138. DS 138 cell mortality was higher than with most of the programs, but 
efficiency was above the average. 
Table 12. Results of Breast CSC pmaxGFP™ nucleofection  
 
Programs selected for the siRNA nucleofection of breast CSC culture were CM 
138 and DS 138. After the 3-day-incubation, nucleofection efficiency was 
determined by the confluency results gained from the phase-contrast IncuCyte. 
 
 
Figure 23. Nucleofection of Breast CSC. 
Breast CSC nucleofection results after the 3-day-incubation. The best nucleofection 
efficacy was achieved with the Nucleofector program DS 138 with approximately 50% 
efficiency. Primary cell line kit P3 was used. The confluency value is relative to 0% 
confluency as a starting point.  
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BT-474 cell culture 
PmaxGFP™ nucleofection was carried out with the Cell Line Kit SF, and the 
siRNA nucleofection with the Cell Line Kit SG. Both of these solution kits were 
suggested by the representative from Lonza. Optimization results gave 
promising results, with almost 60 % of efficacy and only 10 % mortality (Table 
13) with EN 138 program. Viability and GFP-positive cell number were 
determined with 0.4% trypan-blue and CelloMeter. The conditions of the pulse 
program were optimized by following the Lonza guideline (Figure 19 and 24) for 
achieving higher efficacy, even probable cost of viability. SiRNA nucleofection 
was carried out with four different programs:  ED 138, ED 113, ER 137 and DD 
137. Latter pulse program was suggested by the demonstrator from Lonza. 
After the 3-day-incubation, the efficacies of the nucleofections were determined 
by the confluency results gained from a phase-contrast IncuCyte. Results 
showed poor cell viability, less than 60 %, and an approximate of 30 % as the 
nucleofection efficacy (Figure 25). After a further, microscopic visualization, the 
siRNA cell death nucleofected cells were shown to be ruptured, and a clear 
effect on cell proliferation was showed (Figure 26). The relatively high 
conluency value obtained for these “cell death” cells, by the IncuCyte, was 
prooven as a missleading value. The highest cell viability and nucleofection 
efficacy were achieved with ED 137 pulse program.  
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Table 13. Results of BT-474  pmaxGFP™ nucleofection 
Programs that showed most promising reasults for the nucleofection of BT 474 cells 
were CD 137, DS 138, EH 100, and EN 138. From these  four programs four further 
programs were selected for increasing the transfection efficiency. Programs selected 
for the sirRNA transfection were ED 138, ED 113, ER 137, and DD 137 (suggested by 
the representative from Lonza). 
 
 
Figure 24. Optimization of Nucleofection™ Conditions 
A short guideline for the program optimization that was followed for achieving higher 
efficiency. From the default optimization programs (“Best programs”) DS 138, EH 100, 
EN 138 and EW 113 showed the best results. From these four, pulses with “increasing 
efficiency” were selected. Program ER 137 was not obtained from these guidelines; 
program was suggested by a representative.   
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Figure 25. Nucleofection of BT-474.  
BT-474 nucleofection results after the 3-day-incubation. In the figure 15. only the 
highest transfection efficiency and cell viability are shown. Here, the confluency value 
is relative to 0% confluency as a starting point. Nucleofector program ED 137  and Cell 
Line Kit SG were used.  
   
           
 
 
 
 
  
Figure 26. Nucleofected BT-474 cells. 
Image of the cells, captured at the time point after 70-hour-incubation. A) the 
nucleofection of siNEG and b) the nucleofection of cell death. Captured with the phase-
contrast IncuCyte. Nucleofector program ED 113 was used with the Cell line Kit SG. 
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7.3 ALDH activity 
Fluorescent, ALDH overexpressing cells were first detected by Envision 
multilabel scanning program and visualized by fluorescent microscope. ALDH 
activity has been successfully detected with FACS, flow cytometry. Multilabel 
reader has been successfully used for identifying ALDHbr in prostate cancer 
cells in 384-format (Ketola et al 2011). This 384-HT-reader based format was 
being tested and seen if microscopic visualization could be used for the 
detection.  
384-well format – Adherent Cells 
Fluorometric results gained with the Envision Multilabel reader showed variable 
results (Table 14.) According to the results, cyclopamine increased the ALDHbr 
of the breast CSC’s when added in high concentrations. Salinomycin treated 
LNCaP cells showed the same effect (Figure 27). Cells with stem-cell properties 
have been found to have decreased ALDHbr value when treated with 
salinomycin and cyclopamine (Ketola et al 2011; Bar et al 2008). Both of these 
drugs were diluted in DMSO, so that DMSO treated cells were used as an 
appropriate control. ALDH –ve samples, where DEAB was used as an inhibitor 
of ALDH, showed only a slight inhibition (in LNCaP cells) and a slight increase 
in ALDHbr (in breast CSC). 
Table 14. Results of ALDEFLUOR® Assay for Adherent Cells.  
Detection values achieved with Envision multilable reader. Measurements gave 
inconsistent values; no accurate conclusions could be made.   
Chemical Treatment LNCaP  Breast CSC 
ALDH +ve 283 183 273 085 
DMSO 179 694 108 621 
salinomycin 1 µM 302 271 203 564 
cyclopamine 5 µM 225 658 266 478 
cyclopamine 10 µM 171 083 310 357 
ALDH –ve (DEAB) 256 628 279 774 
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Figure 27. ALDHbr detection of LNCaP and Breast CSC cell cultures. 
Detection values are relative to ALDH+ve cells. Salinomycin and cyclopamine were 
added as known ALDHbr decreasing drugs. LNCaP cells seem to behave as expected 
in case of cyclopamine and DMSO treated cells. Breast CSC’s seemed to behave as 
expected with salinomycin and DMSO. Because of the variation, any conclusions could 
not be made. 
Visualization of the ALDEFLUOR® stained cells on 384-well plate was done 
with the fluorescent microscope, cGFP and eGFP filters. However, there was 
fluorescent signal only detected with LNCaP cells (Figure 28). 
 
Figure 28. ALDEFLUOR® stained LNCaP cells 
Aldefluor® treated LNCaP cells, cultured on a 384-well plate (black, Corning). Cells 
captured with a fluorescence microscope (5x) with eGFP filter. 
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Cells in Suspension 
ALDEFLUOR® treated cells were suspended and pipetted into the wells of 384-
well plate and the fluorometric signal was detected with Envision multilabel 
reader. Detection values were set against with the background. ALDH inhibitor 
DEAB systematically showed higher ALDHbr (Figure 29). DEAB was used as a 
negative control, so no conclusions could be made. The only observation was 
on the decrease of fluorometric signal during the time course. Highest 
fluorometric signal was detected straight after the ALDEFLUOR® treatment. 
After 12 hours since the treatment the signal showed stabilization for as long as 
72 hours since the treatment. Sample plate was kept on ice or in +4°C. 
 
Figure 29. ALDHbr detection of SK-BR 3 and Breast CSC cell cultures. 
Detection values are relative to the background (empty wells).First detection was 
applied after 30minutes of the ALDEFLUOR® substrate treatment. After every 
detection, sample plate was placed on ice or +4°C. ALDH inhibitor was showing no 
effect or even increased ALDHbr. Fluorometric signal was shown to degrease already 
between 30mins and 2hours. 
Visualization of the ALDEFLUOR® stained cells was done with the fluorescent 
microscope, cGFP and eGFP filters (Figures 30 and 31). Suspension cells were 
pipetted onto a glass microscopic slide. ALDEFLUOR® stained cells were 
assumptioned to be successfully visualized (Figure 32)(Stemcell-technology 
ALDFELUOR®-protocol). 
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Figure 30 ALDEFLUOR® treated SK-BR 3 cells.  
Aldefluor® treated SK-BR 3 cells captured with fluorescence microscope (40x) on a 
glass microscopic slide. A) Cells visualized with phase-contrast filter and b) with eGFP 
filter 
 
 
 
   
 
Figure 31. ALDEFLUOR® treated breast CSC cells,  
Aldefluor® treated breast CSC’s captured with fluorescence microscope (10x) on a 
glass microscopic slide. A) cells visualized with phase-contrast filter and b) with eGFP 
filter. 
    
 
 
 
Figure 32. ALDEFLUOR® stained SK-BR 3 cells 
Fluorescent and phase images of ALDEFLUOR® stained cells a) “SKBR3 is brightly 
stained with ALDEFLUOR® due to high expression of ALDH (expression indicated by 
flow cytometry)” b) ” DEAB control of SKBR3 cells show dim fluorescence” and c) 
“Brighfield images of SKBR3 monolayers” (Stemcell Technologies, “Identification of 
ALDH-expressing cancer stem cells” –technical bulletin) 
 
          a        b 
          a        b 
           a                                     b                              c 
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8 DISCUSSION 
Chemical Transfection and Nucleofector technology 
When applying a chemical transfection method for HTS format there are a 
number of requirements for the protocol and the assay development requires 
standardization as far as possible. For this reason the concentration of siRNA, 
the cell number and the volume of the medium were kept constant during all the 
experiments. Optimization in this case comprised trial and error experiments 
with the concentration of the reagent before finding the right volume for each 
cell line and culture. Transfection conditions always vary between cell lines, 
especially between hard-to-transfect cell lines and cancer stem cell cultures. 
The variation is due to the characteristics of the cells and the conditions require 
optimization before the actual research work. Other than the technical factors 
mentioned above, the condition of the cell is a crucial factor which also affects 
the transfection result. Eight different commercial transfection reagents were 
tested for two cancer stem cell cultures and five other cell cultures. Since no 
single transfection reagent or delivery method can be applied for all types of 
cells, each of these reagents was tested with every culture. Depending on the 
reagent, the efficiency and the cytotoxicity of the transfection may vary greatly. 
SiLentFect (Bio-Rad) is now commonly used at VTT and achieves moderate 
results with normal cell lines and low results with stem cell cultures. The 
optimization results of this study were compared with the results obtained with 
SiLentFect. The transfection reagents used in this study were selected because 
of different reasons; some of reagents were selected because of the 
manufacturer had a ready protocol suiting HTS-format, or because of the 
promises as an effective and non-toxic reagent for stem and primary cells, or 
purely because of the financial point-of-view. From these eight reagents, the 
highest transfection efficiency values (60-80%) for the MCF-7, A-172 and U-87 
MG cell lines with about 60-90 % cell viability were obtained with SiLentFect 
#2281A and volumes of 0.07 to 0.09 µl per well. HiPerFect (Qiagen) showed 
promising results also at small concentrations, from only 0.03 to 0.05 µl per 
well. A mortality rate of only 10-20 % was exhibited with 70-80 % transfection 
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efficiency. The HiPerFect HTS reagent is targeted for siRNA and miRNA 
transfections in 384-format and is provided with a ready-to-use reverse 
transfection protocol. TrueFect-Lipo transfection reagent gave also promising 
results, and in some cases even better transfection efficacy values than other 
reagents. But TrueFect-Lipo was found as non-efficient by the financial point-of-
view. 
The transfection of cancer stem cells, epithelial cell culture and BT-474 was 
proven efficient with the Nucleofector® device. With the Cell Line Kit P3 more 
than 50 % nucleofection efficacy was obtained for these cells while chemical 
transfection was approximately 50 %. Bigger difference was seen on the 
mortality rate, as chemical transfection showed more cytotoxic effects than the 
Nucleofector transfection. With the chemical transfection of the BT-474 cell 
culture, the transfection efficacy was 55% with 20% mortality, pmaxGFP ® 
vector nucleofection of these same cells gave promising suggestions with 60 % 
efficacy and 10% mortality. However, siRNA nucleofection was concluded with 
a different Cell Line Kit than the optimization, and the siRNA nucleofection 
efficacy was only 30%. The pmaxGFP® vector nucleofection was concluded 
with the Cell Line Kit SF, which suggests higher efficacy for BT-474 cell culture 
nucleofection than the Cell Line Kit SG. Pulse program EN 138 was found to be 
optimal for BT-474 cells. Nucleofection technology was shown to be a useful 
and powerful tool for primary and stem cells and other hard-to-transfect cells. 
The nucleofector™ 16-model program was found useful for medium-throughput 
transfections. Now also a 384-well version is available but at a very high cost. 
ALDH activity 
The overexpression of aldehyde dehydrogenase has been identified as a 
marker for cells with stem-cell properties (Charafe-Jauffret et al 2009). The 
ALDEFLUOR™ Kit (STEMCELL technology) has enabled the identification and 
isolation of these stem-like cells from cancer cell cultures. The protocol of the kit 
is developed for cells in suspension and detection of the aldefluor fluorescence 
(ALDHbr) is intended to be carried out by fluorescence-activated cell sorting 
(FACS) flow cytometry. The protocol was further developed for HT-based,  
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384-format, adherent prostate cell cultures (Ketola et al 2011) with the detection 
by Envision Multilabel reader. Here the aim was also to develop the assay 
further for breast cancer stem cells. ALDHbr detection results obtained from this 
work were, however, inconsistent and visualization suggested cell rupturing 
caused by the ALDEFLUOR® assay treatment.  
The ALDHbr of dead and ruptured cells has been shown to have decreased 
(Figure 32). Cells were cultured on a black 384-well plate in order to achieve 
advantageous results by multilabel reading, which for its part may have caused 
only faint or no fluorescence signal visualization with a microscope even though 
Envision detection suggested otherwise. The 384-format protocol for adherent 
cell cultures was aimed to be tested and extended for an automated technique. 
SK-BR 3 cells were known to be high in ALDH1A1 expression (Charafe-Jaffraut 
et al 2009), wherefore they were used as a positive control in the ALDHbr 
determination of breast cancer stem cells. Cells were suspended for the assay, 
and plated on a black 384-well plate for Envision detection. The fluorescent 
stain was successfully visualized (Figures 30 and 31), and Envision multilabel 
reader values suggested high ALDHbr. However, the results could not be 
reported to be successful since the negative control, DEAB, showed an 
increase in the detection values. The increase could be explained by the high 
overexpression of aldefluor hydrogenase when the recommended DEAB 
concentration is not sufficient for inhibiting the formation of the fluorescence 
substrate. In this case, an increase by the DEAB concentration could give 
reliable results. To further test this assumption, a re-run of the experiment is 
needed. The ALDH activity testing done in this thesis gives some suggestions 
and assumptions, but scientific evidence or technical improvement was not 
achieved. 
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                                                                                                 Appendix 1
   
Complete Cell Growth Media 
MCF-7 cell growth medium 
Dulbecco’s Modified Eagle Medium (DMEM, 1000 mg/l glucose) supplemented 
with 2mM Glutamine, 1 % Penicillin/Streptomycin  and 10 % Fetal Bovine 
Serum (FBS) 
BT-474 cell growth medium 
Dulbecco’s Modified Eagle Medium (DMEM, 4500 mg/l glucose) supplemented 
with 1mM Sodium Guryvate, 4mM Glutamine, 0.01 mg/l Insulin, 1% 
Penicillin/Streptomycin, and 10 % FBS 
SK-BR 3 cell growth medium 
McCoy’s 5A Modified Medium supplemented with 1,5 mM Glutamine, 1 % 
Penicillin/Streptomycin, and 10 % FBS 
Glioma CSC 1904 cell growth medium 
Dulbecco’s Modified Eagle Medium (DMEM, 4500 mg/l glucose) and Ham’s F-
12 Glutamax supplemented with 2mM L-Glutamine, 1% Penicillin/Streptomycin, 
and B27 Neuromix (50x), N2 Supplement (100x), and basic Fibroglast Browth 
Factor (bFGF, human recombinant), and Epidermal Growth Facotr (EGF) 
A 172 cell growth medium 
Dulbecco’s Modified Eagle Medium (DMEM, 4500 mg/l glucose) supplemented 
with 1% Penicillin/Streptomycin, and 10 % FBS. 
U-87 MG cell growth medium 
Eagle’s Minimum Essential Medium supplemented with 10 % FBS 
 
 
